Skip to main content

Table 3 Adjusted hazard ratios (95%CI) for overall survival and recurrence-free survival by tumor CYP27A1 expression in BC-blood cohort

From: CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients

  Model 0a Model 1b Model 2c
Cases Events CYP27A1 high vs low HR (95%CI) Cases Events CYP27A1 high vs low HR (95%CI) Cases Events CYP27A1 high vs low HR (95%CI)b
Follow-up period ≤ 5 years
Overall survival
  All 808 61 1.90 (1.12–3.23) 805 59 1.40 (0.77–2.42) 804 59 1.31 (0.74–2.32)
   P = 0.02    P = 0.28    P = 0.35
  ER+ 697 41 1.84 (0.93–3.62) 695 40 1.90 (0.96–3.77) 694 40 1.93 (0.97–3.85)
   P = 0.07    P = 0.06    P = 0.06
  ER+ and age ≥ 55 yrs 486 37 1.75 (0.84–3.63) 484 36 1.80 (0.86–3.74) 483 36 1.79 (0.85–3.75)
   P = 0.13    P = 0.12    P = 0.12
  ER+ and age < 55 yrs 208 4 4.21 (0.56–31.78) 208 4 3.65 (0.31–42.97) 208 4 2.02 (0.13–30.70)
   P = 0.16    P = 0.30    P = 0.61
Recurrence-free survival
  All 808 99 1.76 (1.15–2.71) 805 97 1.32 (0.84–2.07) 804 97 1.32 (0.83–2.08)
   P = 0.01    P = 0.23    P = 0.24
  ER+ 704 72 1.50 (0.87–2.60) 702 71 1.46 (0.85–2.51) 701 71 1.51 (0.88–2.60)
   P = 0.14    P = 0.17    P = 0.13
  ER+ and age ≥ 55 yrs 490 54 1.12 (0.58–2.17) 488 53 1.15 (0.59–2.24) 487 53 1.16 (0.60–2.26)
   P = 0.73    P = 0.67    P = 0.66
  ER+ and age < 55 yrs 214 18 3.25 (1.20–8.76) 214 18 3.18 (1.08–9.37) 214 18 3.59 (1.15–11.20)
   P = 0.02    P = 0.03    P = 0.03
Follow-up period > 5 years
Overall survival
  All 570 47 1.50 (0.72–2.93) 569 46 1.14 (0.54–2.43) 568 46 1.08 (0.50–2.35)
   P = 0.29    P = 0.73    P = 0.83
  ER+ 509 40 0.96 (0.39–2.35) 508 39 0.77 (0.29–2.01) 507 39 0.79 (0.30–2.08)
   P = 0.93    P = 0.59    P = 0.64
  ER+ and age ≥ 55 yrs 348 31 1.46 (0.43–4.92) 347 30 0.42 (0.10–1.82) 346 30 0.46 (0.11–1.98)
   P = 0.54    P = 0.25    P = 0.30
  ER+ and age < 55 yrs 124 9 0.38 (0.08–1.70) 124 9 1.60 (0.35–7.46) 124 9 1.69 (0.33–8.73)
   P = 0.41    P = 0.55    P = 0.53
Recurrence-free survival
  All 527 74 1.3 (0.77–2.31) 522 75 1.19 (0.67–2.12) 521 75 1.22 (0.68–2.18)
   P = 0.29    P = 0.54    P = 0.50
  ER+ 474 67 0.83 (0.45–1.54) 470 68 1.01 (0.53–1.90) 469 68 1.05 (0.56–2.00)
   P = 0.56    P = 0.99    P = 0.87
  ER+ and age ≥ 55 yrs 328 51 0.91 (0.44–1.91) 324 51 0.91 (0.42–1.98) 323 51 0.97 (0.44–2.10)
   P = 0.81    P = 0.82    P = 0.93
  ER+ and age < 55 yrs 123 16 0.66 (0.21–2.08) 124 17 1.10 (0.35–3.51) 124 17 1.24 (0.36–4.20)
   P = 0.48    P = 0.87    P = 0.73
  1. HR hazard ratio, CI confidence interval, ER+ estrogen receptor positive
  2. aModel 0: adjusted for FFPE block storage duration
  3. bModel 1: adjusted for age at diagnosis, tumor size, lymph node involvement, ER expression, tumor histological grade and FFPE block storage duration
  4. cModel 2: Model 1 + adjusted for local (radiotherapy) and systemic (endocrine and chemotherapy) treatments